Iovance Biotherapeutics, Inc. IOVA R2KR3KPHARMA
Company Overview
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.07.
Recent Developments
- Dec 2025 Revenue of $263.50M (+60.6% YoY); net profit $-390.98M.
- Trailing 12 Months Year-on-year growth — revenue +65.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 65.70% |
Stock Price Performance
| 1 Year: | +258.78% |
| 6 Months: | +71.35% |
| 3 Months: | +107.80% |
| 1 Month: | +41.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)69.84 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IOVA Iovance Biotherapeutics, Inc. R2KR3KPHARMA | 8.79 | -12.74 | $3.92B | 0.00% | -52.06% | -55.97% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 238.00K | 469.00K | 715.00K | 31.11M | 58.55M | 49.32M | 59.95M | 67.45M | 71.43M | 99.31M |
| Operating Income | -6.44M | -7.64M | - | -7.01M | -11.73M | -18.98M | - | -20.88M | -23.58M | -22.34M | - | -26.88M | -31.38M | -35.06M | - | -39.99M | -50.16M | -51.61M | - | -70.81M | -63.63M | -58.97M | - | -75.57M | -81.43M | -86.24M | -91.71M | -99.73M | -100.39M | -110.86M | -110.09M | -118.36M | -117.72M | -101.91M | -89.07M | -121.22M | -113.77M | -94.90M | -81.04M | -51.91M |
| Net Income | -6.37M | -7.63M | -8.36M | -6.88M | -11.56M | -68.21M | -15.69M | -20.68M | -23.38M | -22.15M | -25.85M | -26.52M | -30.66M | -33.83M | -32.58M | -36.95M | -47.55M | -49.49M | -63.57M | -69.59M | -63.02M | -58.57M | -68.40M | -75.45M | -81.35M | -86.12M | -91.61M | -99.35M | -99.62M | -107.37M | -106.53M | -113.76M | -112.98M | -97.10M | -83.54M | -116.16M | -111.66M | -91.25M | -79.05M | -47.31M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.47 | -0.40 | - | -0.51 | -0.53 | -0.55 | -0.58 | -0.63 | -0.63 | -0.50 | -0.47 | -0.46 | -0.42 | -0.34 | -0.28 | -0.36 | -0.33 | - | -0.19 | -0.11 |
| R&D Expense | 4.05M | 4.96M | - | 4.19M | 4.46M | 8.48M | - | 15.59M | 18.65M | 16.68M | - | 19.91M | 24.55M | 27.95M | - | 30.91M | 39.30M | 41.58M | - | 56.95M | 49.27M | 43.05M | - | 55.95M | 62.12M | 65.36M | 68.30M | 73.41M | 72.50M | 82.73M | 86.35M | 87.53M | 79.78M | 62.08M | 67.04M | 75.97M | 79.36M | 75.17M | 62.49M | 58.85M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | 1.19M | 164.07M | 263.50M |
| Operating Income | - | -15.77K | -815.41K | -21.22M | -8.13M | -22.64M | -12.04M | -27.86M | -53.64M | -92.88M | -128.26M | -206.87M | -261.94M | -342.70M | -398.88M | -460.56M | -395.28M | -403.36M |
| Net Income | -58.72K | -15.77K | -1.61M | -25.69M | -3.31M | -25.38M | -12.04M | -27.66M | -52.89M | -92.06M | -123.58M | -197.56M | -259.58M | -342.25M | -395.89M | -444.04M | -372.18M | -390.98M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -1.59 | -1.88 | -2.23 | -2.49 | -1.89 | -1.28 | -1.09 |
| R&D Expense | - | 0 | 171.48K | 1.76M | 1.66M | 2.15M | 3.85M | 15.47M | 26.94M | 71.61M | 99.83M | 166.02M | 201.73M | 259.04M | 294.78M | 333.19M | 276.23M | 300.27M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2007 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | 1.46M | 568.43K | 29.41K | 19.87M | 46.51M | 105.65M | 171.89M | 155.37M | 480.82M | 344.65M | 768.46M | - | 663.98M | 780.35M | 910.43M | 913.17M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 479.12M | 307.85M | 457.02M | 442.69M |
| Cash & Equivalents | 0 | 0 | 2.90K | 8.26K | 1.29M | 510.22K | 0 | 19.67M | 44.91M | 33.59M | 106.72M | 145.37M | 82.15M | 13.97M | 67.33M | - | 231.73M | 114.89M | 115.69M | 163.08M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 10.37M | 51.52M | 51.68M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 151.00K | 69.34M | 82.45M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | 9.89M | 14.63M | 45.68M | 111.96M | - | 164.34M | 195.74M | 200.02M | 214.59M |
| Current Liabilities | - | - | - | - | 822.87K | 13.35M | 11.35M | 2.27M | 1.66M | 1.63M | 4.97M | 9.60M | 14.40M | 39.08M | 54.87M | - | 91.48M | 110.31M | 122.34M | 138.36M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00M | 1.00M | 1.00M | 1.00M | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 85.45M | 75.86M | 58.26M | 49.44M |
| Total Equity | 8.00K | 61.00K | 2.28K | -13.49K | 638.09K | -12.78M | -11.32M | 17.60M | 44.84M | 104.02M | 166.92M | 145.48M | 466.19M | 298.97M | 656.50M | - | 499.64M | 584.61M | 710.40M | 698.58M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 187.81M | 256.14M | 305.25M | 411.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.45K | -620.80K | -6.19M | -2.24M | -3.66M | 8.63M | -18.38M | -32.67M | -78.71M | -101.25M | -158.89M | -205.13M | -227.94M | -292.76M | -361.82M | -352.98M | -302.41M |
| Investing Cash Flow | 0 | 0 | -81.05K | 0 | -12.71K | - | -71.21M | 8.89M | 58.68M | -386.28M | 90.03M | -317.85M | 132.00K | 256.45M | -155.24M | -96.41M | 47.50M |
| Financing Cash Flow | 19.80K | 1.91M | 5.49M | 1.73M | 23.35M | - | 78.27M | 96.90M | 58.69M | 424.31M | 6.13M | 576.42M | 239.27M | 190.15M | 462.96M | 390.66M | 300.77M |
| Capital Expenditure | -0 | -0 | -31.05K | -0 | -13.00K | -1.59M | -1.14M | -1.52M | -1.03M | -1.20M | -6.92M | -46.79M | -37.57M | -20.43M | -22.29M | -11.07M | -33.84M |
| Free Cash Flow | -14.45K | -620.80K | -6.22M | -2.24M | -3.68M | 7.04M | -19.52M | -34.19M | -79.74M | -102.45M | -165.81M | -251.93M | -265.51M | -313.18M | -384.11M | -364.05M | -336.24M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -38,735.0% | -240.9% | -153.1% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -37,345.4% | -226.8% | -148.4% |
| ROE % | -2,570.8% | 116.9% | -252.0% | 201.0% | 29.2% | -144.2% | -26.8% | -26.6% | -31.7% | -63.3% | -26.5% | -66.1% | -39.5% | - | -79.2% | -76.0% | -52.4% | -56.0% |
| ROCE % | - | - | -127.8% | 166.0% | 71.8% | -128.6% | -26.9% | -26.8% | -32.1% | -63.7% | -27.5% | -67.7% | -36.7% | - | -69.7% | -68.7% | -50.2% | -52.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.16% | 36.96M | $296.03M |
| 2 | MHR Fund Management, LLC | 6.39% | 28.97M | $232.03M |
| 3 | State Street Corporation | 5.40% | 24.48M | $196.07M |
| 4 | Two Sigma Investments, LP | 4.20% | 19.01M | $152.28M |
| 5 | Vanguard Capital Management LLC | 4.02% | 18.20M | $145.82M |
| 6 | Vanguard Portfolio Management LLC | 3.18% | 14.39M | $115.26M |
| 7 | Geode Capital Management, LLC | 2.28% | 10.32M | $82.70M |
| 8 | Millennium Management Llc | 1.88% | 8.53M | $68.29M |
| 9 | Dimensional Fund Advisors LP | 1.43% | 6.46M | $51.75M |
| 10 | Palo Alto Investors Lp | 1.17% | 5.30M | $42.42M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IOVA
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQWWw1ampPTzk1VlpUYnh2NjJtcnRxcmZiVEl2b19mWUhyWjJMa1JTWmYtUGtsZlRGLVZNaWw3OWtzRndXVWg0cUVmY09QbUhXUTFyaC1rNFJ3UWdMTUJ2Yzkxc1hoblRhUzRnTEpxcnp2dEtOczFCTUtKYTloSTBEcEdITjkyZ0tWODY5VX…
Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPTmwzZUdodjhPZk1OVHluZGtiUHVRMFl1bVIwV29NeTE1NFpMQVhTblBKYzRrVGtFcWZBNVIxTHA2cDBORDEyUTdCdmp5MFl0Q05XS3h3NmVCTXZ2dnpza3JlUEItU2FKTHpqMnRTU3F5aVlIdElnaEo4OHR1Y3A5VzNySVY3a0xZYnZ6cm…
Iovance Biotherapeutics (IOVA) Stock Looks Pricey Given Its Sales Outlook - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNSXlPLXZUY1hkUmxaWDZ0bEJWR29EeUp3WGhhQWxZMFR0Y0RJTFN2ZUIzS3dCbW5vNzRfd3k3RE56eHNLMmdMa2tlRjR0dEtuM1BnaWp1RDlfdVhfNTVNSGV0d2V4TTV4ckdkTFpzMkl0QmZZOFUwOWhBNGZvM0VNSEVpVl85VnNSMDVmUD…
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOS1h5Vm4tSFpKbUVQemx1M0twY3IxaV85LTdOcE5fWWpuWDgxLXBxZXpQYVNrWUJ5M2lKeEZwS3RuZHh5dXNfaVliRUZzRWktaGJONUNoZkhjQ3ZNa1VNOWhfWUNRTk9lTkUtRW9aM2dvcW5POTdBZ2M3bGJpbktTcmRSbDFXTkU5OXNnMD…
UBS Lifts Iovance Biotherapeutics Price Target as Cancer Drug Sales Top Expectations - TIKR.com
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPTGRrVzJzOTVFeHZKNDJmM2ppc2xyZGptb2hIVlI2NnotMXJkTUc4RWd6WlQxYWlJNGFQaVE3OG4zbUppTl9DdnNjMDlhdm95WkN5RWw4NGptR185R1phY1FEVWpRUklONy1LdHJreHNJYWs3V0ZYTC1NTk1teEprT1RDY0xKWHBiekx3Qm…
IOVA Stock Heads For Best Day In Over 6 Years – Buyout Buzz Builds After Blowout Q2 - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPZ0tEUEZIM1dtYTFpX08zWHoteWxURktMMHFJaGpPUzVDZks1aWt5MWNkTW1CcWwzaVVnYjM4aVFjb1lNU2duaUp3eWdMeHlYc3p3LXotUHhRcjFCWVB6Zl9XTFZhQjR2bWV3UlRpQ0YwcEgwQTZZdWMybXpQNDg2dzRVMWZ1RWZnZmtJd0…
IOVA — Frequently Asked Questions
What is the current share price of Iovance Biotherapeutics, Inc. (IOVA)?
As of 2026-09-07 16:24 PDT, Iovance Biotherapeutics, Inc. (IOVA) trades at $8.79 on NasdaqGM. Its 52-week range is $1.81 to $8.99.
What is the market capitalisation of IOVA?
Iovance Biotherapeutics, Inc. (IOVA) has a market capitalisation of $3.92B on NasdaqGM.
What is the P/E ratio of IOVA?
IOVA trades at a trailing price-to-earnings (P/E) ratio of -12.74. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.85.
What is the return on equity (ROE) of IOVA?
IOVA has a return on equity (ROE) of -55.97%. Its return on capital employed (ROCE) is -52.06%.
Is IOVA a good stock to buy?
This page provides a data-driven analysis of Iovance Biotherapeutics, Inc. (IOVA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.